Table 1 Phenotype comparison of GRAS patients sorted by BAIAP3 genotypes.

Males

n =471−538^b

n = 155−187^b

n = 474−538^b

n =152−175^b

Target variables

Benzo use disorder (n (%))

11 (2.3)

9 (5.4)

0.047 (χ² = 3.93)

11 (2.3)

9 (5.7)

0.034 (χ² = 4.47)

Anxiety composite score (mean ± SD)^c,d

−0.06 ± 0.74

−0.07 ± 0.70

0.499 (F = 0.46)

−0.07 ± 0.73

−0.05 ± 0.72

0.651 (F = 0.21)

Sociodemographic

Age (at examination) (years) (mean ± SD (range))

37.33 ± 12.01 (18–78)

36.17 ± 11.91 (17–75)

0.225 (Z = −1.21)

37.28 ± 11.96 (18–78)

36.34 ± 12.06 (17–75)

0.309 (Z=−1.02)

Education (years) (mean ± SD (range))^e

14.17 ±3.48 (8–28)

14.42 ± 3.70 (8–27)

0.680 (Z=−0.41)

14.21 ±3.48 (8–28)

14.32 ± 3.76 (8–27)

0.853 (Z = −0.19)

Unemployment (n (%))

217 (44.7)

76 (44.7)

0.990 (χ² = 0.00)

214 (44.2)

75 (46.6)

0.601 (χ² = 0.27)

Substance use

Alcohol use disorder according to DSM-IV-TR (n (%))

221 (42.3)

84 (45.7)

0.435 (χ² = 0.61)

217(41.6)

82 (47.4)

0.180 (χ²= 1.80)

Cannabis use disorder according to DSM-IV-TR (n (%))

218(41.8)

83 (45.1)

0.430 (χ² = 0.62)

224 (42.9)

75 (43.4)

0.919 (χ² = 0.01)

Clinical

PANSS positive score (mean ± SD (range))

13.55 ±6.04 (7–36)

14.02 ±6.41 (7–38)

0.427 (Z =−0.79)

13.53 ±6.03 (7–36)

14.23 ± 6.50 (7–38)

0.249 (Z=−1.15)

Chlorpromazine equivalents (mean ± SD (range))

707.90 ± 694.69

689.45 ± 568.91

0.678 (Z=−0.42)

701.33 ±688.16

712.11 ± 592.75

0.424 (Z=−0.80)

(0–6,324.29)

(0–3,238.00)

(0–6,324.29)

(0–3,238.00)

GAF score (mean ± SD (range))

45.70 ± 16.04 (10–90)

45.35 ± 16.88 (5–90)

0.862 (Z =−0.17)

45.75 ± 16.05 (10–90)

44.90 ± 16.89 (5–90)

0.619 (Z= −0.50)

Females

n = 223–269^b

n = 75–92 ^b

n = 229–273^b

n = 71–83^b

Target variables

Benzo use disorder (n (%))

12 (4.7)

6 (7.0)

0.406 (χ² = 0.69)

12 (4.6)

6 (7.7)

0.281 (χ² = 1.16)

Anxiety composite score (mean ± SD)^c,d

−0.02 ±0.77

0.19 ± 0.80

0.028 (F = 4.91)

−0.02 ± 0.78

0.21 ± 0.77

0.017 (F= 5.81)

Sociodemographic

Age (at examination) (years) (mean ± SD (range))

42.36 ± 12.92 (18–79)

44.86 ± 12.52 (21–76)

0.893 (T= 1.61)

42.52 ± 12.90 (18–79)

44.49 ± 12.60 (20–76)

0.221 (T = 1.23)

Education (years) (mean ± SD (range))^e

14.56 ±3.95 (7–31)

14.12 ±3.54 (8–27)

0.447 (Z = −0.76)

14.52 ±3.94 (7–31)

14.13 ±3.62 (8–27)

0.454 (Z = −0.75)

Unemployment (n (%))

76 (31.9)

20 (25.0)

0.243 (χ²= 1.37)

74 (30.5)

20 (28.2)

0.712 (χ² = 0.14)

Substance use

Alcohol use disorder according to DSM-IV-TR (n (%))

59 (22.4)

14 (15.7)

0.178 (χ²= 1.82)

60 (22.4)

13(16.0)

0.219 (χ² = 1.51)

Cannabis use disorder according to DSM-IV-TR (n (%))

30 (11.4)

8 (9.0)

0.525 (χ² = 0.40)

29 (10.8)

9(11.1)

0.941 (χ² = 0.01)

Clinical

PANSS positive score (mean ± SD (range))

13.84 ±6.66 (7–37)

14.41 ±6.38 (7–33)

0.288 (Z = −1.06)

13.87 ± 6.69 (7–37)

14.32 ±6.24 (7–32)

0.366 (Z =–0.91)

Chlorpromazine equivalents (mean ± SD (range))

636.37 ± 776.51

704.59 ± 762.50

0.612 (Z =–0.51)

634.40 ±771.10

718.83 ± 788.67

0.616 (Z =−0.50)

(0–7,375.00)

(0–4,370.00)

(0–7,375.00)

(0–4,370.00)

GAF score (mean ± SD (range))

46.34 ± 19.42 (8–90)

44.22 ± 17.59 (12–84)

0.435 (Z =−0.78)

46.22 ± 19.25 (8–90)

44.88 ± 18.07 (12–84)

0.645 (Z =−0.46)